119
Participants
Start Date
February 5, 2019
Primary Completion Date
May 28, 2024
Study Completion Date
May 28, 2024
EOS100850
Oral administration
Pembrolizumab
IV Infusion
Chemotherapy
Standard of Care IV Infusion
Institut Jules Bordet, Anderlecht
UCL Saint-Luc, Brussels
Hospital GZA Sint-Augustinus, Wilrijk
UZ Ghent, Ghent
Onkologikoa, San Sebastián
START Madrid-HM CIOCC Hospital Universitario HM Sanchinarro, Madrid
Universidad de Navarra - Clinica Universitaria de Navarra, Pamplona
Centre de Lutte Contre le Cancer - Institut de Cancerologie de l'Ouest - Rene Gauducheau, Saint-Herblain
Karmanos Cancer Institute, Michigan Center
Centre de Lutte Contre le Cancer (CLCC) - Universite de Lyon - Centre Leon-Berard, Lyon
Centre Hospitalier Universitaire de Poitiers - Hopital la Miletrie- Pôle Régional de Cancérologie, Poitiers
Gustave Roussy, Villejuif
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack
University of Texas Health Science Center at San Antonio, San Antonio
Yonsei University Severance Hospital, Seoul
Samsung Medical Center, Seoul
St Mary's Hospital, The Catholic University of Korea, Seoul
Hospital del Mar, Barcelona
The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital, Sutton
Lead Sponsor
iTeos Belgium SA
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
iTeos Therapeutics
INDUSTRY